Literature DB >> 3417226

Amiodarone-induced hepatic phospholipidosis: a morphological alteration independent of pseudoalcoholic liver disease.

B Guigui1, S Perrot, J P Berry, J Fleury-Feith, N Martin, J M Métreau, D Dhumeaux, E S Zafrani.   

Abstract

In order to study the relationship between amiodarone-induced hepatic phospholipidosis and liver disease, liver biopsies obtained from 13 patients treated with amiodarone for 4 months to 15 years were investigated by light and electron microscopy. Light microscopy showed pseudoalcoholic liver lesions that were probably related to amiodarone in four cases, various alterations (i.e. cirrhosis, three cases; steatosis and fibrosis, two cases; chronic venous congestion, one case; acute hepatitis, one case) that could be explained by another cause than amiodarone in seven cases and normal liver in two cases. In all cases, electron microscopy showed intralysosomal myelin figures suggestive of phospholipidosis. These myelin figures were associated with intralysosomal electron-dense deposits. In the four cases in which analysis by electron microprobe was performed, it demonstrated large amounts of iodine in the electron-dense deposit-containing lysosomes, indicating the accumulation of amiodarone. These results show that hepatic phospholipidosis is constantly observed in amiodarone-treated patients, whether or not pseudoalcoholic liver lesions are present. This phospholipidosis, which could be only a morphological marker of intrahepatic accumulation of the drug, should not therefore be considered grounds for attributing liver disease to the drug.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3417226     DOI: 10.1002/hep.1840080514

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  15 in total

1.  Liver cirrhosis induced by long-term administration of a daily low dose of amiodarone: a case report.

Authors:  Hiroki Oikawa; Chihaya Maesawa; Ryo Sato; Kanta Oikawa; Hiroyuki Yamada; Seizo Oriso; Sadahide Ono; Akiko Yashima-Abo; Koji Kotani; Kazuyuki Suzuki; Tomoyuki Masuda
Journal:  World J Gastroenterol       Date:  2005-09-14       Impact factor: 5.742

Review 2.  Drug-induced steatohepatitis.

Authors:  Vaishali Patel; Arun J Sanyal
Journal:  Clin Liver Dis       Date:  2013-09-04       Impact factor: 6.126

3.  Role of vitamin-E on rat liver-amiodarone: an ultrastructural study.

Authors:  Mohamed Samir A Zaki; Refaat A Eid
Journal:  Saudi J Gastroenterol       Date:  2009-04       Impact factor: 2.485

4.  Amiodarone and bepridil inhibit anthrax toxin entry into host cells.

Authors:  Ana M Sanchez; Diane Thomas; Eugene J Gillespie; Robert Damoiseaux; Joseph Rogers; Jonathan P Saxe; Jing Huang; Marianne Manchester; Kenneth A Bradley
Journal:  Antimicrob Agents Chemother       Date:  2007-05-07       Impact factor: 5.191

Review 5.  Drug induced phospholipidosis: an acquired lysosomal storage disorder.

Authors:  James A Shayman; Akira Abe
Journal:  Biochim Biophys Acta       Date:  2012-08-30

Review 6.  Other types of diffuse liver disease: is there a way to do it?

Authors:  Hilton Leao Filho; Camila Vilela de Oliveira; Natally Horvat
Journal:  Abdom Radiol (NY)       Date:  2020-11

7.  Secondary causes of nonalcoholic fatty liver disease.

Authors:  Jacob M Kneeman; Joseph Misdraji; Kathleen E Corey
Journal:  Therap Adv Gastroenterol       Date:  2012-05       Impact factor: 4.409

8.  Severe cholestatic jaundice in the elderly induced by low-dose amiodarone.

Authors:  Nimer Assy; G Khair; Sorina Schlesinger; Osamah Hussein
Journal:  Dig Dis Sci       Date:  2004-03       Impact factor: 3.487

9.  Identification of drugs inducing phospholipidosis by novel in vitro data.

Authors:  Markus Muehlbacher; Philipp Tripal; Florian Roas; Johannes Kornhuber
Journal:  ChemMedChem       Date:  2012-09-03       Impact factor: 3.466

10.  Amiodarone-induced cirrhosis of liver: what predicts mortality?

Authors:  Nasir Hussain; Anirban Bhattacharyya; Suartcha Prueksaritanond
Journal:  ISRN Cardiol       Date:  2013-03-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.